Recent advancements in the treatment of chronic myelogenous leukemia

Michael E. O'Dwyer, Michael J. Mauro, Brian J. Druker

Research output: Contribution to journalReview article

57 Scopus citations

Abstract

Chronic myelogenous leukemia (CML) is a clonal hematopoetic stem cell disorder characterized by the Philadelphia chromosome and resultant production of the constitutively activated Bcr-Abl tyrosine kinase. Characterized clinically by marked myeloid proliferation, it invariably terminates in an acute leukemia. Conventional therapeutic options include interferon-based regimens and stem cell transplantation, with stem cell transplantation being the only curative therapy. Through rational drug development, STI571, a Bcr-Abl tyrosine kinase inhibitor, has emerged as a paradigm for gene product targeted therapy, offering new hope for expanded treatment options for patients with CML.

Original languageEnglish (US)
Pages (from-to)369-381
Number of pages13
JournalAnnual review of medicine
Volume53
DOIs
StatePublished - Mar 9 2002

Keywords

  • Bcr-Abl
  • CML
  • STI571
  • Tyrosine kinase
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Recent advancements in the treatment of chronic myelogenous leukemia'. Together they form a unique fingerprint.

  • Cite this